Human TRAIL R2/TNFRSF10B Antibody | R&D Systems MAB631-100 product information

product summary

company name :

R&D Systems

product type :

antibody

product name :

Human TRAIL R2/TNFRSF10B Antibody

catalog :

MAB631-100

quantity :

100 ug (also 25 ug, 500 ug)

price :

469 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

71903

reactivity :

human

application :

immunohistochemistry - paraffin section

more info or order :

R&D Systems product webpage

citations: 17

Reference
Phillips K, Wright N, McDermott E, Cross N. TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma. Biochem Biophys Res Commun. 2019;517:383-389 pubmed publisher
Onoe Takahashi A, Suzuki Karasaki M, Suzuki Karasaki M, Ochiai T, Suzuki Karasaki Y. Autophagy inhibitors regulate TRAIL sensitivity in human malignant cells by targeting the mitochondrial network and calcium dynamics. Int J Oncol. 2019;54:1734-1746 pubmed publisher
Pan L, Fu T, Zhao W, Zhao L, Chen W, Qiu C, et al. Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling. Cell. 2019;176:1477-1489.e14 pubmed publisher
Boettcher M, Covarrubias S, Biton A, Blau J, Wang H, Zaitlen N, et al. Tracing cellular heterogeneity in pooled genetic screens via multi-level barcoding. BMC Genomics. 2019;20:107 pubmed publisher
Ohshima Y, Takata N, Suzuki Karasaki M, Yoshida Y, Tokuhashi Y, Suzuki Karasaki Y. Disrupting mitochondrial Ca2+ homeostasis causes tumor-selective TRAIL sensitization through mitochondrial network abnormalities. Int J Oncol. 2017;51:1146-1158 pubmed publisher
El Zawily A, Toosi B, Freywald T, Indukuri V, Vizeacoumar F, Leary S, et al. The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation. Oncotarget. 2016;7:77865-77877 pubmed publisher
Lewis A, Valley C, Peery S, Brummel B, Braun A, Karim C, et al. Death Receptor 5 Networks Require Membrane Cholesterol for Proper Structure and Function. J Mol Biol. 2016;428:4843-4855 pubmed publisher
Kang Z, Goldstein S, Yu Y, Meltzer P, Loeb D, Cao L. Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma. Br J Cancer. 2015;113:894-901 pubmed publisher
Suzuki Karasaki Y, Fujiwara K, Saito K, Suzuki Karasaki M, Ochiai T, Soma M. Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarization. Oncotarget. 2015;6:21572-88 pubmed
Bozza W, Di X, Takeda K, Rivera Rosado L, Pariser S, Zhang B. The use of a stably expressed FRET biosensor for determining the potency of cancer drugs. PLoS ONE. 2014;9:e107010 pubmed publisher
Meng X, Koh B, Zhang J, Flatten K, Schneider P, Billadeau D, et al. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem. 2014;289:20543-58 pubmed
Matte I, Lane D, Boivin M, Rancourt C, Piche A. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer. 2014;14:234 pubmed publisher
Piechocki M, Wu G, Jones R, Jacob J, Gibson H, Ethier S, et al. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. Int J Cancer. 2012;131:2562-72 pubmed publisher
Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 2011;17:3181-92 pubmed publisher
Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood. 2009;114:3854-63 pubmed publisher
Locklin R, Federici E, Espina B, Hulley P, Russell R, Edwards C. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther. 2007;6:3219-28 pubmed
Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene. 2003;22:1653-62 pubmed

product information

brand :

R&D Systems

master code :

MAB631

SKU :

MAB631-100

product name :

Human TRAIL R2/TNFRSF10B Antibody

unit size :

100 ug (also 25 ug, 500 ug)

seo description :

The Human TRAIL R2/TNFRSF10B Antibody from R&D Systems is a mouse monoclonal antibody to TRAILR2/TNFRSF10B. This antibody reacts with human. The Human TRAIL R2/TNFRSF10B Antibody has been validated for the following applications: Functional Assay,Immunohistochemistry-Paraffin,Agonist Activity.

target :

TRAIL R2/TNFRSF10B

category :

Primary Antibodies

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.

clonality :

Monoclonal

clone :

71903

conjugate :

Unconjugated

dilution :

Agonist Activity 2-12 ng/mL

host :

Mouse

immunogen :

Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B, Met1-Glu182, Accession # CAG46696

isotype :

IgG1

purity :

Protein A or G purified from hybridoma culture supernatant

species :

Human

specificity :

Detects human TRAIL R2/TNFRSF10B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R3, rhTRAIL R4, or rhDcR3.

gene symbol :

TNFRSF10B

endotoxin note :

<0.10 EU per 1 ╡g of the antibody by the LAL method.

top caption :

Human TRAIL R2/TNFRSF10B Antibody Induces Apoptosis of Jurkat Cells.

accessionNumbers :

CAG46696

applications :

Agonist Activity,Immunohistochemistry-Paraffin,Functional Assay

USD :

469 USD

alt names :

CD262, CD262 antigen, death domain containing receptor for TRAIL/Apo-2L, Death receptor 5, DR5, DR5TRICK2B, Fas-like protein, KILLER/DR5, KILLERapoptosis inducing protein TRICK2A/2B, TNF-related apoptosis-inducing ligand receptor 2, TNFRSF10B, TRAIL receptor 2, TRAILR2, TRAIL-R2apoptosis inducing receptor TRAIL-R2, TRAILR2cytotoxic TRAIL receptor-2, TRICK2, TRICK2A, TRICKB, tumor necrosis factor receptor superfamily member 10B, tumor necrosis factor receptor superfamily, member 10b, tumor necrosis factor receptor-like protein ZTNFR9, ZTNFR9

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage